Trial Profile

A clinical study of to evaluate the safety and efficacy of ELI-002 in combination with Libtayo® (cemiplimab) in patients with KRAS-driven tumors

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 21 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; ELI 002 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Elicio Therapeutics

21 May 2022 New trial record
16 May 2022 According to an Elicio Therapeutics media release, this study which is expected to begin in 2023, will be conducted by Elicio Therapeutics. The companies will provide their respective agent for the trial.
16 May 2022 According to an Elicio Therapeutics media release, the company has entered into a clinical supply agreement with Regeneron o evaluate the safety and efficacy of ELI-002 in combination with Regeneron's Libtayo (cemiplimab) in patients with KRAS-driven tumors.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com